SCHEMBL1477034

SCHEMBL1477034

NCc1cc(-c2ccco2)on1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 2/20 0.47
RAB9A P51151 10/20 0.46
NPC1 O15118 9/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
ALDH1A1 P00352 5/20 0.46
MAPT P10636 3/20 0.46
KDM4E B2RXH2 1/20 0.46
BLM P54132 1/20 0.46
SMN1; SMN2 Q16637 4/20 0.44
HPGD P15428 3/20 0.44
GAA P10253 2/20 0.44
TAAR1 Q96RJ0 1/20 0.44
CYP1A2 P05177 1/20 0.44
LMNA P02545 1/20 0.44
TP53 P04637 1/20 0.44
POLB P06746 3/20 0.44
KMT2A Q03164 1/20 0.44
HTT P42858 1/20 0.43
TSHR P16473 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20507209 0.82 RAB9A (0.52) EPHX2RAB9ANPC1L3MBTL1ALDH1A1
SCHEMBL10274628 0.82 RAB9A (0.51) EPHX2RAB9ANPC1L3MBTL1ALDH1A1
SCHEMBL1474547 0.82 NOTUM (0.59) EPHX2RAB9ANPC1L3MBTL1ALDH1A1
SCHEMBL14948947 0.78 RAB9A (0.55) EPHX2RAB9ANPC1L3MBTL1ALDH1A1
SCHEMBL17790250 0.78 EPHX2 (0.53) EPHX2RAB9ANPC1L3MBTL1ALDH1A1
SCHEMBL1474304 0.76 ALDH1A1 (0.55) RAB9ANPC1L3MBTL1ALDH1A1MAPT
SCHEMBL17788637 0.74 EPHX2 (0.50) EPHX2RAB9ANPC1L3MBTL1ALDH1A1
SCHEMBL14946441 0.74 RAB9A (0.52) EPHX2RAB9ANPC1L3MBTL1ALDH1A1
SCHEMBL13863579 0.74 EPHX2 (0.42) EPHX2RAB9ANPC1L3MBTL1ALDH1A1
SCHEMBL1457325 0.74 NOTUM (0.68) RAB9ANPC1L3MBTL1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3016951-B1 TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2017-05-31 EP disclosed
EP-1971600-B1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK BIOPHARMACEUTICALS CO LTD (KR) 2013-08-21 EP disclosed
US-7915297-B2 Isoxazole derivatives and use thereof SK HOLDINGS CO., LTD. (KR) 2011-03-29 US disclosed
US-7915297-B2 Isoxazole derivatives and use thereof SK HOLDINGS CO., LTD. (KR) 2011-03-29 US disclosed
US-7915297-B2 Isoxazole derivatives and use thereof SK HOLDINGS CO., LTD. (KR) 2011-03-29 US disclosed
US-20090131336-A1 Isoxazole Derivatives and Use Thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-05-21 US disclosed
US-20090131336-A1 Isoxazole Derivatives and Use Thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-05-21 US disclosed
US-20090131336-A1 Isoxazole Derivatives and Use Thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-05-21 US disclosed
EP-1971600-A1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK Holdings Co., Ltd. (KR) 2008-09-24 EP disclosed
WO-2007078113-A1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK HOLDINGS CO., LTD. (KR) 2007-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131336-A1 Isoxazole Derivatives and Use Thereof WNT3A, WNT1, WNT3 EPHX2 2685/4885RAB9A 2013/4885NPC1 2242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.